Natera, Inc. - Common Stock (NQ:NTRA)

419.46 +9.11 (+2.22%)

Delayed Quote Updated: 12:25 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

April 13, 2026

From Natera, Inc.

Via Business Wire

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

April 09, 2026

From Natera, Inc.

Via Business Wire

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

April 09, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

3 Reasons NTRA Has Explosive Upside Potential

April 09, 2026

Even during a down period for the markets, Natera has gone against the grain, climbing to $211.23. Its shares have yielded a 22.1% return over the last six m...

Via StockStory

Natera Inc. (NASDAQ:NTRA) Crushes Q4 Earnings Estimates with Strong Oncology Growth ↗

February 26, 2026

Via Chartmill

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

April 07, 2026

From Natera, Inc.

Via Business Wire

SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery

March 31, 2026

From Natera, Inc.

Via Business Wire

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Government Stocks

Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics

March 23, 2026

CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)...

Via MarketMinute

Topics Supply Chain

1 Unprofitable Stock to Own for Decades and 2 Facing Headwinds

March 20, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 We Question

March 19, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

March 16, 2026

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...

Via StockStory

Topics Economy Stocks

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

March 16, 2026

From Natera, Inc.

Via Business Wire

3 Growth Stocks to Add to Your Roster

March 16, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

3 Market-Beating Stocks to Target This Week

March 13, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Via StockStory

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

March 12, 2026

From Natera, Inc.

Via Business Wire

3 Healthcare Stocks to Target This Week

March 09, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se...

Via StockStory

Natera (NTRA) Stock Trades Up, Here Is Why

March 03, 2026

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 4.3% in the afternoon session after Canaccord Genuity reiterated its Buy rating...

Via StockStory

Topics Economy

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics.

Via The Motley Fool

Topics Lawsuit

Why Natera (NTRA) Shares Are Falling Today

February 27, 2026

Shares of genetic testing company Natera (NASDAQ:NTRA). fell 8.3% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated...

Via StockStory

Topics Earnings Economy

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

February 27, 2026

From Natera, Inc.

Via Business Wire

Natera (NTRA) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Natera (NTRA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

From Natera, Inc.

Via Business Wire

Natera Earnings: What To Look For From NTRA

February 24, 2026

Genetic testing company Natera (NASDAQ:NTRA). will be reporting results this Thursday afternoon. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence World Trade

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

February 24, 2026

From Natera, Inc.

Via Business Wire

Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks ↗

February 21, 2026

These two stocks are core holdings in the legendary investor's portfolio.

Via The Motley Fool

Topics Artificial Intelligence Earnings

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

February 17, 2026

From Natera, Inc.

Via Business Wire

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

February 06, 2026

From Natera, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.